Top image

Our Research

Here you'll find information about our Flagship programs and other projects. Use the filters below to display research of interest using one of the three categories.
  • T1,T2 | Flagship 3 Scholarships & Awards
    Implications of Homologous Recombination Deficiency defects in Advanced Prostate Cancer
    The 5-year survival for patients treated with anti-PD-1 in NSCLC is ~16%. We currently have no reliable tool for predicting who will benefit from this relatively tolerable single drug, and who ...
    BiomarkersGenetics/genomicsImmunotherapyLung cancer
  • T2,T3 | Flagship 3 Scholarships & Awards
    Patient experience of uncertainty when undergoing genomic testing
    This project will aim to understand patient experience of uncertainty when having cancer genomic testing, using questionnaires and interviews to investigate types, levels, predictors and impac...
    Genetics/genomicsPsychosocialAnxietyDepression
  • T1,T2,T3 | Flagship 3 Scholarships & Awards
    Implications of Homologous Recombination Deficiency defects in Advanced Prostate Cancer
    Up to 12% of men with metastatic prostate cancer carry a mutation in a gene that predisposes to cancer, independent of age at diagnosis or family history of cancer. The nCCN guidelines have re...
    Prevention and Early DetectionUrogenitalProstate
  • T1,T2 | Flagship 3 Scholarships & Awards
    RNA 5-hydroxymethylation in Haemopoiesis and Leukaemia
    My project will characterise the role of RNA modifications in normal bone marrow development and acute myeloid leukaemia, focusing on understanding how epigenetic drugs work and exploring new ...
  • T1 | Flagship 3 Scholarships & Awards
    Understanding molecular mechanisms of drug resistance at single cell resolution using biomimetic tissue engineering
     |  This project aims to understand the role of a protein called ERp57, which is expressed by ovarian cancer cells, in the suppression of a part of the innate immune ...
    Urogenital
  • T1,T2 | Flagship 3 Scholarships & Awards
    Understanding molecular mechanisms of drug resistance at single cell resolution using biomimetic tissue engineering
    Acquired drug resistance of cancer cells is one of the major challenges in having successful cancer treatment. Despite the advances of our understanding in cancer, the mechanisms and effects o...
    Treatment
  • T3 | Flagship 3 Scholarships & Awards
    The costs, benefits and preferences for adjuvant immunotherapy in melanoma patients.
      Immunotherapy treatment for melanoma is costly to the health system, patients and to the wider community. Health economic evalution is an important tool to assist in proritising healt...
    ImmunotherapyCancer costsSkin cancerTreatment
  • T1 | Flagship 3 Scholarships & Awards
    Identification and development of efficacious alternative immunotherapies for melanoma patients resistant to current anti-PD-1 and anti-CTLA-4 treatments
    Melanoma is Australia's national cancer and the most deadly cancer in young Australians. Despite the success of anti-PD1/anti-CTLA-4 therapy in advanced stage melanoma, the majority of patient...
    Skin cancer
  • T2,T3 | Flagship 2 Pilot and Seed
    Body composition changes in cancer patients during chemotherapy
    Chemotherapy dosing is generally determined by a patient's height and weight. This does not account for their body composition and can be inaccurate, particularly in people who are obese or un...
    Personalised medicineNew therapies and diagnosticsColorectal cancer
  • T1,T2 | Flagship 2 Pilot and Seed
    Systematic effects of Gioblastoma multiforme (GBM) and GBM-released extracellular vesicles on immune suppression: implications for dendritic cell-based vaccine therapy against GBM
    Despite recent improvements in cancer therapies, the median survival for patients with brain tumours is only 15 months. We need to urgently develop better treatment options. Anti-tumour vaccin...
    Dendritic cell